Woman with Sickle Cell Disease with Current Sigmoid Sinus Thrombosis and History of Inadequate Warfarin Use during a Past Thrombotic Event

We report a 20-year-old woman with sickle cell disease (SCD) who presented with a severe pulsating headache, nausea, and vomiting. Her history was significant for a past thrombotic event during which she had not used anticoagulation therapy as prescribed. Her mental status was mildly confused. On funduscopic examination, papilledema and retinal hemorrhages were found. Results of a computed tomogram were normal. A lumbar puncture demonstrated increased intracranial pressure (60 cm H2O). Magnetic resonance venography demonstrated a right sigmoid sinus thrombosis. Although SCD has been reported as a cause of thrombotic dural venous sinus events, this case increases the knowledge about neurological complications of SCD. The patient was treated with low molecular weight heparin, blood transfusions, acetazolamide, and methylprednisolone, and her symptoms and signs resolved

New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma

Purpose: Propranolol, a non-selective β-adrenergic receptor blocker, has been used for the treatment of the patients with hypertension for more than 50 years. There are several in vitro and in vivo evidences that β-adrenergic receptor antagonists inhibit proliferation and angiogenesis and also increase apoptosis in breast, skin, and colon cancers. The aim of this study was to investigate the cytotoxic and apoptotic effects of propranolol and the genes involved in propranolol-induced apoptosis in multiple myeloma cells. Methods: Time-dependent antiproliferation and apoptotic effects of propranolol were subsequently determined by MTT cell proliferation assay, changes in caspase-3 activity, loss of mitochondrial membrane potential (MMP), and also the localization of phosphatidylserine in the plasma membrane. Changes in expression levels of NF-ΚB pathway were examined by qRT-PCR array. Results: IC50 values of propranolol on U266 cells were calculated as 141, 100, and 75 μM after 24-, 48-, and 72-h propranolol exposure, respectively. There were significant increases in caspase-3 activity, loss of MMP, and increases in apoptotic cell population in response to propranolol in U266 cells in a time- and dose-dependent manner. There were increases in expression levels of BCL10, TRAF family members, interleukins, TLR1-4, TNFRSF10B, NF-κB, and the inhibitors of NF-κB genes, and significant decreases in expression levels of Bcl-2 in response to propranolol treatment were observed. Conclusion: These results revealed that propranolol has antiproliferative and apoptotic effects on multiple myeloma cells. Being supported with in vivo analyses, propranolol can be a good and economical way to treat multiple myeloma patients.Turkish Academy of Sciences Outstanding Young Investigator Programm

Yüksek voltajlı iletim hatlarından kaynaklanan elektrımanyetik alan ile hematolojik maligniteler ilişkisi

TEZ4933Tez (Uzmanlık) -- Çukurova Üniversitesi, Adana, 2004.Kaynakça (s. 39-50) var.viii, 65 s. ; res. ; 30 cm.

Kronik böbrek yetmezliğinde eritrosit membran atpaz enzimi ve hemodializ ile peritoneal dializin enzim üzerine etkisi

TEZ107Tez (Uzmanlık) -- Çukurova Üniversitesi, Adana, 1981.Kaynakça (s. [54]-65) var.65 s. : res. ; 31 cm.

Pankreasın Ekstra-Medüller Miyeloid Tümörü: Olgu Sunumu ve Literatürün Gözden Geçirilmesi

Extramedüller miyeloid tümörler (EMMT) miyeloid hücrelerin neoplazileridir. Bu tümörler bütün organlarda oluşabilir fakat bazı lokalizasyonlarda EMMT saptanması nadirdir ve pankreasın EMMT ile tutulumu da nadirdir. Burada allogeneik kök hücre naklinden 4 yıl sonra gelişen pankreas EMMT'ü sunulmuş ve mevcut bilgi gözden geçirilmiştirExtramedullary myeloid tumors (EMMTs) are the tumors of myeloid cells. These tumors may occur in all of the organs of the body, but some localizations are rare. Pancreatic involvement of EMMTs is a rare entity. Here we report a case of EMMT of the pancreas 4 years after allogeneic stem cell transplantation and we review the existing data about EMMTs involving the pancrea

Demir Eksikliği Anemisi Tedavisinde RDW’nin Dalgalı Seyri ve Klinik Önemi

Giriş: RDW, kan sayımının rutin bir parametresidir. Bu parametrenin kullanımı genel olarak mikrositer anemilerin ayırıcı tanısıyla kısıtlıdır. Bununla birlikte literatürde demir eksikliği anemisinin tedavisinde RDW’ nin seyri ve klinik önemiyle ilgili yeteri kadar bilgi bulunmamaktadır. Bundan dolayı bu çalışmada RDW’ nin demir eksikliği anemisinin tedavisindeki seyri ve hemoglobin artışı ile ilişkisinin araştırılması amaçlanmıştır. Method: Demir eksikliği anemisi tanısı konulan 105 hasta bu çalışmaya alınmıştır. Bulgular: Tanı anındaki ve tedavi başlandıktan sonraki 1, 2 ve 3. aydaki ortalama hemoglobin değerleri sırasıyla 9.2±1.5, 11.7±1.0, 12.7±0.8 ve 13.1±0.8 g/dL, RDW değerleri sırasıyla %18.4±2.6, %26.4±6.5, %17.8±4.3 ve %14.7±1.7 bulundu. Tanı anında ve 1. aydaki RDW değerleri arasında istatistiksel olarak belirgin artış (p<0.0001), 1, 2 ve 3. aydaki RDW değerleri arasında belirgin azalma (p<0.0001) tespit edildi. Regresyon analizinde 1. aydaki RDW artışı ile 1, 2 ve 3. aylardaki hemoglobin artışları arasında doğrusal bir bağlantı olduğu görüldü (sırasıyla p<0.0001, r=0.461; p<0.0001, r=0.51; p<0.0001, r=0.472). Sonuç: Bu çalışmanın sonuçlarına göre, RDW’ de meydana gelen artışın demir tedavisi yanıtını öngördürmek için kullanılabileceğini düşünmekteyiz.Background: Red cell distribution width (RDW) is a routine parameter of blood count. The use of this parameter is generally restricted to the differential diagnosis of microcytic anemia. However, there is insufficient published data on the course of RDW in the treatment of iron deficiency anemia and on its clinical importance. Therefore, this study investigated the course of RDW in the treatment of iron deficiency anemia and its association with increased hemoglobin values. Methods: One hundred five patients diagnosed with iron deficiency anemia were enrolled in this study. Results: The mean hemoglobin values of patients at diagnosis and at 1, 2 and 3 months after initiation of treatment were 9.2±1.5, 11.7±1.0, 12.7±0.8, and 13.1±0.8 g/dL, respectively. The mean RDW values of patients at diagnosis and 1, 2 and 3 months after initiation of treatment were 18.4±2.6, 26.4±6.5, 17.8±4.3, and 14.7±1.7%, respectively. Between baseline and 1 month of treatment there was a significant increase in RDW values (<0.0001), and between 1, 2 and 3 months there was a significant decrease in RDW values (<0.0001). Regression analysis revealed a linear correlation between the increase in RDW at month 1 and increase in hemoglobin level at months 1, 2 and 3 (<0.0001, r=0.461; <0.0001, r=0.51; <0.0001, r=0.472, respectively). Conclusion: We suggest that an increase in RDW may be used to predict the response to iron treatment